| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.22M | $10.50M | - | |
| CFO | 235.0K | $1.11M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2024 | Sinha Vikas84 | See Remarks | Sell | 885 | $0.77 | $683.22 | - | -4.9% | -54.3% | |
| Feb 21, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 8,252 | $0.70 | $5,803.29 | -0.5% | +11.8% | -40.0% | |
| Feb 20, 2024 | Miller Edward82 | General Counsel | Sell | 385 | $0.70 | $267.65 | -0.2% | +9.2% | -35.7% | |
| Feb 20, 2024 | Sinha Vikas84 | See Remarks | Sell | 2,893 | $0.70 | $2,011.21 | -0.3% | +9.2% | -35.7% | |
| Feb 20, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 494 | $0.70 | $343.43 | -0.6% | +9.2% | -35.7% | |
| Feb 8, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 11,150 | $0.67 | $7,493.92 | -12.3% | +16.2% | -35.0% | |
| Feb 5, 2024 | Sinha Vikas84 | See Remarks | Sell | 18,331 | $0.67 | $12,281.77 | -1.6% | +20.3% | -34.7% | |
| Feb 5, 2024 | Miller Edward82 | General Counsel | Sell | 8,869 | $0.67 | $5,942.23 | -3.8% | +20.3% | -34.7% | |
| Feb 5, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 5,792 | $0.67 | $3,880.64 | -6.0% | +20.3% | -34.7% | |
| Feb 5, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 41,421 | $0.67 | $27,752.07 | -4.8% | +20.3% | -34.7% |